THE EFFECT OF TAMSULOSIN AND DUTASTERIDE COMBINATION THERAPY ON LOWER URINARY TRACT SYMPTOMS IN PATIENT WITH BENIGN PROSTATIC HYPERPLASIA
Main Article Content
Abstract
Background: Lower urinary tract symptoms in elderly men has many etiologies, the most common one among them is benign prostatic hyperplasia. Medical therapy is recommended as the first-line treatment option. In this regard, the combination of tamsulosin and dutasteride has been shown to be effective and beneficial. Objectives: To evaluate the effectiveness of tamsulosin and dutasteride combination therapy in male patient has lower urinary tract symptoms due to benign prostatic hyperplasia. Materials and methods: A cross-sectional descriptive study was conducted on 62 patients with lower urinary tract symptoms due to benign prostatic hyperplasia who were treated with a combination of tamsulosin 0.4mg and dutasteride 0.5mg for 3 months. Results: In this study, the mean age of the patients was 68.94 ± 8.81 years, 51.6% of the patients were sexually active, the mean IPSS score was 16.82 ± 2.15, the mean Qol score was 3.73 ± 0.7, the mean prostate volume was 48.14 ± 11.88 ml (31.96%), and the mean PSA level was 3.24 ± 2.68 ng/ml. The prevalence of urinary tract infection (UTI) associated with BPH was 19.4%. After 3 months, combination therapy with the two drugs reduced the IPSS score by 4.52 points and improved quality of life by 1.68 points after 3 months, prostate volume decreased by 24.7% and serum PSA level decreased by 39.5% after 3 months, the incidence of acute urinary retention decreased from 16.13% to 3.2%, the incidence of BPH-related surgery was 6.5%, and the rate of clinical progression was 8.06%. The success rate (p) is 90.3%. The side effects of combination therapy were low, with the most common being erectile dysfunction (4.8%).Conclusion: Combination therapy with tamsulosin and dutasteride is highly effective in treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), reducing the risk of clinical progression, acute urinary retention, and BPH-related surgery.
Article Details
Keywords
Tamsulosin, dutasteride, combination therapy, benign prostatic hyperplasia
References
2. McConnell JD, Roehrborn CG, Oliver OM et MTOPS Research Group. The long term effect of doxazosin, finasteride and combinationbtherapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003, 349, 2385-2396, DOI: 10.1056/NEJMoa030656.
3. Roehrborn C, Siami P, Barkin J, Damião R, MajorWalker K, Nandy I et al. The effects of combination therapy with dutasteride andtamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010. 57, 123-131, https://doi.org/10.1016/j.eururo.2009.09.035.
4. Barry MJ, Williford WO, Chang W, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol. 1995. 154(5), 1770–1774, https://doi.org/10.1016/S0022-5347(01)66780-6.
5. Nguyễn Văn Triệu. Hiệu quả kết hợp các thuốc alpha blocker và ức chế 5 alpha reductase trong điều trị bệnh nhân tăng sản lành tính tuyến tiền liệt. Tạp chí Y Dược lâm sàng 108. 2021. Tập 16, https://doi.org/10.52389/ydls.v16iDB4.1030.
6. Nguyễn Trường An. Nghiên cứu nồng độ kháng nguyên đặc hiệu tuyến tiền liệt trong huyết thanh của nam giới ≥ 50 tuổi bị tăng sinh lành tính tuyến tiền liệt và một số yếu tố liên quan.
Tạp chí Y Dược học - Trường Đại học Y Dược Huế. 2023 Số 3, tập 13, DOI:
10.34071/jmp.2023.3.4.
7. Nguyễn Hoài Bắc, Hạ Hồng Cường. Khảo sát nồng độ PSA ở những nam giới có triệu chứng đường tiểu dưới trên 45 tuổi tại Bệnh viện Đại học Y Hà Nội. Tạp chí Nghiên cứu Y học. 2022. 149(1), 162-171, http://thuvienso.thanglong.edu.vn/handle/TLU/6151.
8. Roehrborn C, Oyarzabal Perez I, Roos E,Calomfirescu N, Brotherton B, Wang F et. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®)) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice,in the management of treatment-naïve men withmoderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015. 116, 450-459, https://doi.org/10.1111/bju.13033.
9. MONDA, JEFFREY M., and JOSEPH E. OESTERLING. Medical treatment of benign prostatic hyperplasia: 5α-reductase inhibitors and α-adrenergic antagonists. Mayo Clinic Proceedings.1993 Vol. 68. No. 7. Elsevier, https://doi.org/10.1016/S0025-6196(12)60603-X.
10. Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004. 46(4), 488–495, https://doi.org/10.1016/j.eururo.2004.05.008.
11. Naslund, M., Eaddy, M., Hogue, S., Kruep, E. and Shah, M. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. Curr Med Res Opin. 2009. 25, u72663–2669. https://doi.org/10.1185/03007990903210330.
12. Rosen, Raymond C., et al. Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): a post hoc analysis of a prospective randomised placebocontrolled study. International Journal of Clinical Practice. 2019. 73.9, 1-9. https://doi.org/10.1111/ijcp.13282.